PDE7 inhibitor S14

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562239

CAS#: 18741-24-7

Description: PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor. It acts by targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element binding protein (CREB) pathway, exerting neuroprotection in an Alzheimer's disease (AD) model.


Price and Availability

Size
Price

Size
Price

Size
Price

PDE7 inhibitor S14 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 10 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 562239
Name: PDE7 inhibitor S14
CAS#: 18741-24-7
Chemical Formula: C14H10N2OS
Exact Mass: 254.0514
Molecular Weight: 254.3
Elemental Analysis: C, 66.12; H, 3.96; N, 11.02; O, 6.29; S, 12.61


Synonym: PDE7 inhibitor S14; PDE7 inhibitor-S14; S14;

IUPAC/Chemical Name: 3-Phenyl-2-sulfanylquinazolin-4(3H)-one

InChi Key: CRGOYNYLYMPGKH-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10N2OS/c17-13-11-8-4-5-9-12(11)15-14(18)16(13)10-6-2-1-3-7-10/h1-9H,(H,15,18)

SMILES Code: O=C1N(C2=CC=CC=C2)C(S)=NC3=C1C=CC=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Bartolome F, de la Cueva M, Pascual C, Antequera D, Fernandez T, Gil C, Martinez A, Carro E. Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimers Res Ther. 2018 Feb 20;10(1):24. doi: 10.1186/s13195-018-0352-4. PubMed PMID: 29458418; PubMed Central PMCID: PMC5819290.

2: Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, Sanz-SanCristobal M, Lopez-Moreno JA, Gil C, Martinez A, Santos A, Perez-Castillo A. Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. Stem Cells. 2017 Feb;35(2):458-472. doi: 10.1002/stem.2480. Epub 2016 Sep 16. PubMed PMID: 27538853.

3: Morales-Garcia JA, Alonso-Gil S, Gil C, Martinez A, Santos A, Perez-Castillo A. Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. Stem Cells Transl Med. 2015 Jun;4(6):564-75. doi: 10.5966/sctm.2014-0277. Epub 2015 Apr 29. PubMed PMID: 25925836; PubMed Central PMCID: PMC4449102.

4: Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Pérez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A, Carro E. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Sep;34(9):2133-45. doi: 10.1016/j.neurobiolaging.2013.03.011. Epub 2013 Apr 9. PubMed PMID: 23582662.